Internalization and intracellular trafficking of poly(propylene imine) glycodendrimers with maltose shell in melanoma cells

Current Medicinal Chemistry

Volumn 19, Issue 29, 2012, Pages 4955-4968

  Filimon, A ^a   Sima, L E ^a   Appelhans, D ^b   Voit, B ^b   Negroiu, G ^a  

^a INSTITUTE OF BIOCHEMISTRY OF THE ROMANIAN ACADEMY   (Romania)

^b LEIBNIZ INSTITUTE OF POLYMER RESEARCH DRESDEN   (Germany)

Author keywords

Cellular uptake; Glycodendrimers; Intracellular trafficking; Melanoma; Poly(propylene imine) dendrimers; Sugar shell

Indexed keywords

CHOLESTEROL; DENDRIMER; GLYCODENDRIMER; MALTOSE; POLY(PROPYLENE IMINE); POLYPROPYLENE; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; CELL MIGRATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CYTOTOXICITY; DRUG STABILITY; ENDOCYTOSIS; HUMAN; HUMAN CELL; INTERNALIZATION; METASTATIC MELANOMA; PHENOTYPE;

ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; DENDRIMERS; HUMANS; MALTOSE; MELANOMA; MICE; POLYPROPYLENES;

EID: 84870422549     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311209024955     Document Type: Article

References (82)

1. Bharali, D.J.; Khalil, M.; Gurbuz, M.; Simone, T.M.; Mousa, S.A. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int. J. Nanomed., 2009, 4, 1-7.
2. Zhang, L.; Gu, F.X.; Chan, J.M.; Wang, A.Z.; Langer, R.S.; Farokhzad, O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther., 2008, 83, 761-769.
3. Haag, R.; Kratz, F. Polymer Therapeutics: Concepts and Applications. Angew. Chem. Int. Ed., 2006, 45, 1198-1215.
4. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer, 2006, 6, 688-701.
5. Koo, O. M.; Rubinstein, I.; Onyuksel, H. Role of Nanotechnology in Targeted Drug Delivery and imaging: a concise review. Nanomedicine: Nanotechnology, Biology, and Medicine, 2005, 1, 193-212.
6. Soussan, E.; Cassel, S.; Blanzat, M.; Rico-Lattes, I. Drug Delivery by Soft Matter: Matrix and Vesicular Carriers. Angew. Chem., 2009, 121, 280-295.
7. Riehemann, K.; Schneider, S. W.; Luger, T. A.; Godin, B.; Ferrari, M.; Fuchs, H. Nanomedicine - Challenge and Perspectives. Angew. Chem. 2009, 121,886-913.
8. Tekade, R. K.; Kumar, P. V.; Jain, N. K. Dendrimer in Oncology: An expanding Horizon. Chem. Rev., 2009, 109, 49-87.
9. Shen, M.; Shi, X. Dendrimer-based organic/inorganic hybrid nanoparticles in biomedical applications. Nanoscale, 2010, 2, 1596-1610.
10. Bosman, A. W.; Janssen, H. M.; Meijer, E. W. About dendrimers: structure, physical properties, and application. Chem. Rev., 1999, 99, 1665-1688.
11. Boas, U.; Heegard, P.M.H. Dendrimer in drug research. Chem. Soc. Rev., 2004, 33, 43-63.
12. Niederhafner, P.; Sebestik, J.; Jezek, J. Peptide dendrimers. J. Pept. Sci., 2005, 11, 757-788.
13. Wang, Y.; Cao, X.; Guo, R.; Shen, M.; Zhang, M.; Zhu, M.; Shi, X. Targeted delivery of doxorubicin into cancer cells using a folic-acid dendrimer conjugate. Polym. Chem., 2011, 2, 1754-1760.
14. Marano, R.J.; Toth, I.; Wimmer, N.; Brankov, M.; Rakoczy, P.E. Dendrimer delivery of an anti-VEGF oligonucleotide into eya:a log term study into inhibiton of laser-induced CNV, distribution, uptake and toxicity. Gene Ther., 2005, 12, 1544-1550.
15. Mallpeddi, R.; Rohan, L.C. Progress in antiretroviral drug delivery using nanotechnology. Int. J. Nanomedicine, 2010, 5, 533-547.
16. Tyssen, D.; Henderson, S.A.; Johnson, A.; Sterjoviski, J.; Moore, K.; La, J.; Zanin, M.; Sonza S, Karellas, P.; Giannis, M.P.; Krippner, G.; Wesselingh, S.; McCarthy, T.; Gorry, P.R.; Ramsland, P.A.; Cone, R.; Paull, J.A.R.; LewisG.R.; Tachedjian, G. Structure activity relationship of dendrimer microbicides with dual action antiviral activity, PloS One, 2010, 5(8), e12309.
17. Ward, B.B.; Dunham, T.; Majoros, I.J.; Baker, J.R., Jr. Targeted dendrimer chemotherapy in an animal model for head and neck squamous cancer carcinoma. J. Oral Maxil. Surg., 2011, 69, 2452-2459.
18. Li, Z., Huang, P.; Zhang, X.; Lin, J.; Yang, S.; Liu, B.; Gao, F.; Xi, P.; Ren, Q.; Cui, D. RGD-Conjugated dendrimer-modified gold nanoparticles for in vitro tumor targeting and photothermal therapy. Mol. Pharmaceutics, 2009, 7, 94-104.
19. Gingras, M.; Raimundo, J.-M.; Chabre, Y.M. Cleavable dendrimers. Angew. Chem. Int. Ed., 2007, 46, 1010-1017.
20. Shamis, M.; Lode, H.N.; Shabat, D. Self-immolative Dendritic prodrugs by catalytic antibody 38C2. J. Am. Chem. Soc., 2004, 126, 1726-1731.
21. Crampton, H.L.; Simanek, E. Dendrimers as drug delivery vehicles: noncovalent of bioactive compounds with dendrimers. Polym. Int., 2007, 56 484-496.
22. Grinstaff, M.W.; Wolinsky, J.B. Therapeutic and diagnostic applications of dendrimers for cancer therapy. Adv. Drug Deliver. Rev., 2008, 60, 1037-1055.
23. Langereis, S.; Dirksen, A.; Hackeng, T.M.; van Genderen, M.H.P.; Meijer, E.W. Dendrimers and magnetic resonance imaging. New J. Chem., 2007, 31, 1152-1160.
24. Cheng, Y., Zhao, L.; Li, Y.; Xu, T. Design of biocompatible dendrimers for cancer and diagnostic therapy. Chem. Soc. Rev., 2011, 40, 2673-2703.
25. Bezouska, K. Design, functional evaluation and biomedical applications of carbohydrate dendrimers. Rev. Mol. Biotechnol., 2002, 90, 269-290.
26. Li, Y.; Cheng, Y.; Xu, T. Design, synthesis and potent pharmaceutical applications of glycodendrimers, a mini review. Curr. Drug Discov. Technol., 2007, 4, 246-254.
27. Pospisil, M.; Vannucci, L.; Fiserova, A.; Krausova, K.; Horvath, O.; Kren, V.; Mosca, F.; Lindhort, T.K.; Sadalapure, K.; Bezouska, K. Glycodendrimeric ligands of c-type lectin receptors as therapeutic agents in experimental cancer. In: Progress in Basic and Clinical Immunology, Mackiewicz et al, Ed., Kluver Academic Press/Plenum Publisher: New York, 2001, pp. 343-347.
28. Sheng, K.-C.; Kalkanidis, M.; Pouniotis, D.S.; Esparon, S.; Tang, C.K.; Apostolopous, V.; Pietersz, G.A. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur. J. Immunol., 2008, 38, 424-436.
29. Roy, R.; Baek, M.-G. Glycodendrimers:novel glycotype isoesters unmasking sugar coding. Case study with T-antigen markers from breast cancer MUC1 glycoprotein. Rev. Mol. Biotechnol., 2002, 90, 291-309.
30. Shiao, T.C.; Roy, R. Glycodendrimers as functional antigens and antitumor vaccines. New J. Chem., 2012, 36, 324-339.
31. Lagnoux, D.; Darbre, T.; Schmitz, M.L.; Reymond, J.-L. Inhibition of mitosis by glycopeptide dendrimers conjugates of cholchicine. Chem. Eur. J., 2005, 11, 3943-3950.
32. Agrawal, P.; Gupta, U.; Jain, N. K. Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials, 2007, 28, 3349-3359.
33. Appelhans, D.; Komber, H.; Quadir, M.A.; Richter, S.; Schwarz, S.; van der Vlist, J.; Aigner, A.; Müller, M.; Loos, K.; Seidel, J.; Arndt, K.-F.; Haag, R.; Voit, B. Hyperbranched PEI with various oligosaccharide architectures: synthesis, characterization, ATP complexation and cellular uptake. Biomacromolecules, 2009, 10, 1114-1124.
34. Klajnert, B., Appelhans, D.; Komber, H.; Morgner, N.; Schwarz, S.; Richter, S.; Brutschy, B.; Ionov, M.; Tonkikh, A.K.; Bryszewska, M.; Voit, B. The influence of dense organized maltose shells on the biological properties of poly(propylene imine) dendrimers: New effects dependent on hydrogen bonding. Chem. Eur. J., 2008, 14, 7030-7041.
35. Appelhans, D.; Oertel, U.; Mazzeo, R.; Komber, H.; Hoffmann, J.; Weidner, S.; Brutschy, B.; Voit, B.; Ottaviani, M.F. Dense-shell glycodendrimers,: UV-VIS and electron paramagnetic resonance study of metal ion complexation. Proc. R. Soc. A, 2010, 466, 1489-1513.
36. Klementieva, O.; Benseny-Cases, N.; Gella, A.; Appelhans, D.; Voit, B.; Cladera, J. Dense shell glycodendrimers as potential non-toxic antiamyloidigenic angents in Alheimer's disease, Amyloid-dendrimer aggregates morphology and cell toxicity. Biomacromolecules, 2011, 12, 3903-3909.
37. Fischer, M.; Appelhans, D.; Klajnert, B.; Bryszewska, M.; Voit, B.; Rogers, M. The influence of surface functionality of poly(propylene imine) dendrimers on aggregation and propagation of the scrapie prion protein. Biomacromolecules 2010, 11, 1314-1325.
38. Ziemba, B.; Janaszewska, A; Ciepluch, K; Krotewicz, M.; Fogel, W. A.; Appelhans, D.; Voit, B.; Klajnert, B.; Bryszewska, M. In vivo toxicity of poly(propyleneimine) dendrimers. J. Biomed. Mater. Res. A, 2011, 99, 261-268.
39. Mkandawire, M.; Pohl, A.; Gubarevich, T.; Lapina, V.; Appelhans, D.; Rödel, G.; Pompe, W.; Schreiber, J.; Opitz, J.: Selective targeting of green fluorescent nanodiamond conjugates to mitochondria in HeLa cells. J. Biophoton., 2009, 2, 596-606.
40. Köth, A.; Appelhans, D.; Tiersch, B.; Koetz, J.: Use of Weakly Cationic Dendritic Glycopolymer for Morphological Transformation of Phospholipid Vesicles into Tube-like Network. Soft Matter 2011, 7, 10581-10584.
41. Höbel, S.; Loos, A.; Appelhans, D.; Schwarz, S.; Seidel, J.; Voit, B.; Aigner, A. Maltose- and maltotriose-modified, hyperbranched poly(ethylene imine)s (OM-PEIs): physicochemical and biological properties of DNA and siRNA complexes. J. Control. Release, 2011, 149, 146-158.
42. Kubeil, M.; Stephan, H.; Pietzsch, H.-J.; Geipel, G.; Appelhans, D.; Voit, B.; Hoffmann, J.; Brutschy, B.; Mironov, Y. V.; Brylev, K. A.; Fedorov, V. E. Sugar-decorated dendritic nanocarriers: Encapsulation and release of the octahedral rhenium cluster complex [Re6S8(OH)6]4-. Chem. Asian J., 2010, 5, 2507-2514.
43. Fahmi, A.; Pietsch, T.; Appelhans, D.; Gindy, N.; Voit, B.: Water-soluble CdSe Nanoparticles Stabilised by Dense-Shell Glycodendrimers. New J. Chem., 2009, 33, 703-706.
44. Köth, A.; Koetz, J.; Appelhans, D.; Voit, B. Sweet" gold nanoparticles with oligosaccharide-modified poly(ethyleneimine). Colloid Polym. Sci., 2008, 286, 1317-1327.
45. Richter, A.; Jahnke, A.; Zschoche, S.; Zimmermann, R.; Simon, F.; Eichhorn, K.-J.; Voit, B.; Appelhans, D. pH-Stable Hyperbranched Polyethyleneimine-Maltose Films for the Interaction with Phosphate Containing Drugs. New J. Chem. 2010, 34, 2105 - 2108.
46. Ouyang, W.; Müller, M.; Appelhans, D.; Voit, B. In situ ATR-FTIR investigation on the preparation and enantiospectificity of chiral polyelectrolyte multilayers. ACS Appl. Mater. & Interf., 2009, 1, 2878-2885.
47. Janaszewska, A.; Ziemba, B.; Ciepluch, K.; Appelhans, D.; Voit, B.; Klajnert, B.; Bryszewska, M.: Biodistribution of Maltotriose Modified Poly(propylene imine) (PPI) Dendrimers Conjugated with Fluorescein - Proofs of Crossing Blood-brain-barrier. New J. Chem. 2012, 36, 350-353.
48. Janaszewska, A.; Maczynska, K.; Matuszko, G.; Appelhans, D.; Voit, B.; Klajnert, B.; Bryszewska, M. Cytoxicity of PAMAM, PPI, and maltose modified PPI dendrimers in Chinese hamster ovary CHO) and human ovarian carcinoma (SKOV3) cells. New J. Chem., 2012, 36, 428-437.
49. Alexeev, V.; Mucci, T.; Igoucheva, O. Immunotherapeutic strategies for the treatment of malignant melanoma G. Ital. Dermatol. Venerol., 2008, 143, 139-149.
50. Grossman, D.; Altieri, D.C. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic agents strategies. Cancer Metast. Rev., 2001, 20, 3-11.
51. Bei, D.; Meng, J.; Youan, B.-B.C. Engineering nanomedicines for improved melanoma therapy: progress and promises. Nanomedicine, 2010, 5, 1385-1399.
52. Vannucci, L.; Fiserova, A.; Sadalapure, K.; Lindhorst, T.K.; Kuldova, M.; Rossman, P.; Horvath, O.; Kren, V.; Krist, P.; Bezouska, K.; Luptovcova, M.; Mosca, F.; Pospisil, M. Effects N-acetyl-glycosamine-coated glycodendrimers as biological modulators in the B16F10 melanoma model in vivo. Int. J. Oncol., 2003, 23, 285-296.
53. Seib, F.P.; Jones, A.T.; Duncan, R. Comparison of the endocytic properties of linear and branched PEIs, and PAMAM dendrimers in B16F10 melanoma cells. J. Control. Release, 2007, 117, 291-300.
54. Barth, R.F.; Adams, D.M.; Soloway, A.H.; Alam, F.; Darby, M.V. Boronated starburstdendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture. Bioconjug. Chem., 1994, 5, 58-66.
55. Boswell, C.A.; Eck, P.K.; Regino, C.A.; Bernardo, M.; Wong, K.J.; Milenic, D.E.; Choyke, P.L.; Brechbiel, M.W. Synthesis, characterization and biological evaluation of integrin αvβ3 -targeted PAMAM dendrimers. Mol. Pharmaceutics, 2008, 5, 527-539.
56. Iversen, T.-G.; Skotland, T.; Sandvig, K. Endocytosis and intracellular transport of nanoparticles:present knowledge and need for future studies. Nano Today, 2011, 6,176-185.
57. Albertazzi, L.; Serresi, M.; Albanese, A.; Beltram, F. Dendrimer internalization and intracellular trafficking in living cells. Mol. Pharmaceutics, 2010, 7, 680-688.
58. Saovapakhiran, A.; D'Emanuele, A.; Attwood, D.; Penny, J. Surface modification of PAMAM dendrimers modulate the mechanism of cellular internalization. Bioconjug. Chem., 2009, 20, 6930-701.
59. Kitchens, K.M.; Foraker, A.B.; Kolhatkar, R.B.; Swann, P.W.; Ghandehari, H. Endocytosis and interaction of poly(amidoamine) dendrimers with Cac-2 cells. Pharm. Res., 2007, 24, 2138-2145.
60. Meier, F.; Busch, S.; Lasithiotakis, K.; Kulms, D.; Garbe, C.; Maczey, E.; Herlyn, M.; Schittek, B. Combined targeting of MAPK and AKT signilling pathways is a promising strategy for melanoma treatment. British J. Dermatol., 2007, 156, 1204-1213.
61. Chen, K.G.; Valencia, J.C.; Lai, B; Zhang, G.; Paterson, J.K.; Rouzaud, F.; Berens, W.; Wincovitch, S.M.; Garfield, S.H.; Leapman, R.D.; Hearing, V.J.; Gottesman, M.M. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. PNAS, 2006, 103, 9903-9907.
62. Piantelli, M.; Tatone, D.; Castrilli, G.; Savini, F.; Maggiano, N.; Larocca, L.M.; Ranelletti, F.O.; Natali, P.G. Quercetin and tamoxifen sensitize human melanoma cells to hyperthermia. Melanoma Res., 2001, 11, 469-476.
63. Kushimoto, T.; Basrur, V.; Valencia, J.; Matsunaga, J.; Vieira, W.D.; Ferrans, V.J.; Muller, J.; Appella, E.; Hearing, V.JK. A model for melanosome biogenesis based on the purifi cation and analysis of early melanosomes. PNAS, 2001, 98, 10698-10703.
64. Ochwat, D.; Hoja-Łukowicz, D.; Lityńska, A. N-glycoproteins bearing [beta]1-6 branched oligosaccharides from the A375 human melanoma cell line analysed by tandem mass spectrometry. Melanoma Res., 2004, 14, 479-485.
65. Zhu, S.; Hong, M.; Zhang, L.; Tang, G.; Jiang, Y.; Pei, Y. PEGylated PAMAM dendrimer-Doxorubicin conjugates: In vitro evaluation and in vivo tumor accumulation. Pharm. Res., 2009, 27, 161-1174.
66. Hussain, K.M.; Leong, K.L.J.; Ng, M.M.-L.; Chu, J.J.H. The essential role of clathrin-mediated endocytosis in the infectious entry of human enterovirus 71. J. Biol. Chem., 2011, 286, 309-321.
67. Damm, E.-M.; Pelkmans, L.; Kartenbeck, J.; Mezzacasa, A.; Kurzchalia, T.; Helenius, A. Clathrin- and caveolin-1-independent endocytosis entry of simian virus 40 into cells devoid of caveole. J. Cell Biol., 2005, 168, 477-488.
68. Nakashima, H.; Hamamura, K.; Houjou, T.; Taguci, R.; Yamamoto, N.; Mitsudo, K.; Tonhai, I.; Ueda, M.; Urano, T.; Furukawa, K. Overexpression of caveolin-1 in a human melanoma cell line results in dispersion of ganglioside GD3 from lipid rafts and alteration of leading edges leading to attenuation of malignant properties. Cancer Sci., 2001, 98, 512-520.
69. Lee, E.; Knecht, D.A. Visualization of actin dynamics during macropinocytosis and exocytosis. Traffic, 2002, 3, 186-192.
70. Gosse, S.; Aron, Y.; Thevenot, G.; Monsigny, M.; Fajac, I. Cytoskeletal involvement in cellular trafficking of plasmid/PEI derivative complexes. J. Control. Release, 2011, 122, 111-117.
71. Prekeris, R.; Yang, B.; Oorschot, V.; Klumperman, J.; Scheller, R. Differential roles of syntaxin 7 and syntaxin 8 in endosomal trafficking. Mol. Biol. Cell, 1999, 10, 3891-3908.
72. Dorick, P.;Kenworthy, P.;McCann, B.;Warn, R. Circular ruffle formation and closure lead to macropinocytosis in hepatocyte growth factor/scatter factor- treated cells. Eur. J. Cell.Biol, 1993, 61, 44-53.
73. Heck, J.N.; Mellman, D.L.; Ling, K.; Sun, Y.; Wagoner, M.P.; Schill, N.J.; Anderson, R.A. Phosphatidylinositol phosphate family. Crit. Rev. Biochem. Mol. Biol., 2007, 42, 15-39.
74. Lawe, D.C.; Patki, V.; Heller-Harrison, R.; Lambright, D.; Corvera, S. The FIVE domain of early endosome antigen 1 is required for both phosphatidylinositol 3 phosphate and rab5 binding. J. Biol. Chem., 2000, 275, 3699-3705.
75. Chen, X.; Wang, Z. Regulation of epidermal growth factor receptor endocytosis by wortmannin through activation of Rab5 rather than inhibition of phosphatidyl 3-kinase. EMBO Reports, 2001, 2, 842-849.
76. Robineau, S.; Chabre, M.; Antonny, B. Binding site of brefeldin A at the interface between the small G protein ADP-ribosylation factor 1 (ARF1) and the nucleotide-exchange factor Sec7 domain. Proc. Natl. Acad. Sci. USA, 2000, 97, 9913-9918.
77. Sonnichsen, B.; De Renzis, S.; Nielsen, E.; Rietdorf, J.; Zerial, M. Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of rab5, rab4 and rab11. J. Cell Biol., 2001, 149, 901-913.
78. Hillaireau, H.; Convereur, P. Nanocarriers entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci., 2009, 66, 2873-2896.
79. Falcone, S.; Cocucci, E.; Podini, P.; Kirchhausen, T.; Clementi, E.; Meldolesi, J. Macropinocytosis regulated coordination of endocytic and exocytic membrane traffic events. J. Cell Sci., 2006, 119, 4758-4769.
80. Araki, N.; Hamasaki, M.; Egami, Y.; Hatae, T. Effect of 3-methyl adenine on the fusion process of macropinosomes in EGF-stimulated A431 cells. Cell Struct. Funct., 2006, 31, 145-157.
81. Chapman, R.E.; Munro, S. Retrieval of TGN proteins from the cell surface requires endosomal acidification. EMBO J., 1994, 13, 2305-2312.
82. Lai, S.; Hida, K.; Chen, C.; Hanes, J. Characterization of the intracellulardynamics of a non-degradative pathway accessed by polymer nanoparticles. J. Control. Release, 2008, 125, 107-111.